Guardant Health to present data at San Antonio Breast Cancer Symposium demonstrating utility of liquid biopsy in biomarker identification, therapy selection and residual disease detection
30 Novembro 2023 - 10:05AM
Business Wire
- Spotlight sessions highlight role of Guardant blood tests in
tissue-free detection of minimal residual disease and predictive
impact of ctDNA genomic profiling
- MRD study found ctDNA detection after adjuvant therapy using
Guardant Reveal™ was prognostic for distant recurrence of cancer
nearly eight months before detected via standard of care
surveillance
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology
company, will present data showing the utility of liquid biopsy
tests in the management of breast cancer patients at the San
Antonio Breast Cancer Symposium, December 5-9 in San Antonio,
Texas. Highlights of the eight poster presentations include the use
of blood-based testing to identify actionable biomarkers and
predict therapy response in advanced breast cancer, and to detect
residual disease and predict recurrence in patients with
early-stage breast cancer.
“We look forward to sharing new data in San Antonio
demonstrating the utility of liquid biopsy in advancing the
practice of precision oncology for patients with breast cancer,”
said Craig Eagle, Guardant Health chief medical officer. “The
presentations will show how comprehensive genomic profiling and
residual disease detection using blood-based testing provide
critical insights to help oncologists develop personalized
treatment plans that can improve patient outcomes.”
Two studies were selected for spotlight discussions:
- The PlasmaMATCH study assessed the feasibility of ctDNA genomic
profiling for actionable biomarker detection and therapy selection
in patients with advanced breast cancer. This research explores the
use of ctDNA at multiple points in time to predict therapy response
in patients on targeted therapy, including establishing thresholds
that best predict clinical outcomes. Study results show the use of
longitudinal sampling and ctDNA assessment may help in
understanding, predicting and preparing for clinical outcomes in
patients receiving systemic therapy.
- In a large feasibility study of over 300 patients with
early-stage breast cancer, samples were collected about two years
after curative-intent adjuvant chemotherapy and tested with
Guardant Reveal, using epigenomic technology to assess for the
presence of ctDNA. The study found ctDNA detection after adjuvant
therapy was prognostic for distant recurrence, with a median lead
time between detection and clinically observed disease recurrence
of 7.9 months and high specificity. The study also notes that ctDNA
was detected up to 28.6 months prior to clinical recurrence
detection.
Guardant Health poster presentations
Guardant360 and GuardantOMNI
- The prognostic and predictive impact of circulating tumor DNA
(ctDNA) dynamics in patients with metastatic Triple Negative Breast
Cancer (TNBC) on olaparib based therapy: Results from Cohort E of
the PlasmaMATCH trial (Poster spotlight discussion PS06-04)
Guardant360 CDx
- Cell-free tumor DNA analysis in advanced or metastatic breast
cancer patients enrolled in the German registry study PRAEGNANT
(Poster P04-05-03)
Guardant360
- CDK4/6 inhibition is a potential vulnerability in NF1-depleted
ER+ breast cancer (Poster GS01-08)
- Enhancing Informative Outcomes with Liquid Biopsy in a
Real-World Population of Patients with Advanced Breast Cancer:
Analysis of the SOLTI-1903 HOPE Study (Poster P04-14-02)
- Detection of SPEN mutations in advanced breast cancer by
circulating tumor cell-free DNA (Poster P05-14-07)
Guardant Reveal
- Analysis of ctDNA for the detection of minimal residual disease
(MRD) using a tissue-free, multiomic assay in patients with
early-stage breast cancer (Poster spotlight discussion
PS06-06)
Guardant INFORM
- A bedside-to-bench translational analysis demonstrates that NF1
alterations promote CDK4/6 inhibitor (CDK4/6i) resistance in
hormone receptor-positive (HR+) metastatic breast cancer (mBC) (
Poster PO1-23-09)
- Real-world (RW) utilization and patient outcomes across three
CDK4/6 inhibitors in metastatic breast cancer (mBC) (Poster
P04-18-02)
The full abstracts are available on the official SABCS 2023
website.
About Guardant Health
Guardant Health is a leading precision medicine company focused
on guarding wellness and giving every person more time free from
cancer. Founded in 2012, Guardant is transforming patient care by
providing critical insights into what drives disease through its
advanced blood and tissue tests, real-world data and AI analytics.
Guardant tests help improve outcomes across all stages of care,
including screening to find cancer early, monitoring for recurrence
in early-stage cancer, and helping doctors select the best
treatment for patients with advanced cancer. For more information,
visit guardanthealth.com and follow the company on LinkedIn, X
(Twitter) and Facebook.
Guardant Health Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of federal securities laws, including statements
regarding the potential utilities, values, benefits and advantages
of Guardant Health’s liquid biopsy tests or assays, which involve
risks and uncertainties that could cause the actual results to
differ materially from the anticipated results and expectations
expressed in these forward-looking statements. These statements are
based on current expectations, forecasts and assumptions, and
actual outcomes and results could differ materially from these
statements due to a number of factors. These and additional risks
and uncertainties that could affect Guardant Health’s financial and
operating results and cause actual results to differ materially
from those indicated by the forward-looking statements made in this
press release include those discussed under the captions “Risk
Factors” and “Management’s Discussion and Analysis of Financial
Condition and Results of Operation” and elsewhere in its Annual
Report on Form 10-K for the year ended December 31, 2022, and any
current and periodic reports filed with or furnished to the
Securities and Exchange Commission thereafter. The forward-looking
statements in this press release are based on information available
to Guardant Health as of the date hereof, and Guardant Health
disclaims any obligation to update any forward-looking statements
provided to reflect any change in its expectations or any change in
events, conditions, or circumstances on which any such statement is
based, except as required by law. These forward-looking statements
should not be relied upon as representing Guardant Health’s views
as of any date subsequent to the date of this press release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231130360214/en/
Investor Contact: investors@guardanthealth.com
Media Contact: Michael Weist press@guardanthealth.com +1
650-647-3643
Guardant Health (NASDAQ:GH)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Guardant Health (NASDAQ:GH)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024